Is UZEDY Approved for Schizophrenia?
Yes, UZEDY (risperidone) is FDA-approved for schizophrenia in adults. It's a long-acting injectable given subcutaneously once a month or every two months to treat symptoms and prevent relapse.[1]
How Does UZEDY Work for Schizophrenia?
UZEDY releases risperidone steadily over time, blocking dopamine and serotonin receptors in the brain to reduce hallucinations, delusions, and disorganized thinking common in schizophrenia. Clinical trials showed it matches oral risperidone in symptom control, with 80% of patients relapse-free after 56 weeks.[1][2]
Who Makes UZEDY and When Was It Approved?
Teva Pharmaceuticals and MedinCell developed UZEDY. The FDA approved it in April 2023 as the first monthly or bi-monthly subcutaneous antipsychotic option.[1]
How Does UZEDY Compare to Other Schizophrenia Treatments?
Unlike daily oral antipsychotics (e.g., Risperdal tablets), UZEDY requires fewer injections and avoids first-pass metabolism for more consistent dosing. It outperforms some long-acting injectables like Invega Hafyera in patient preference studies due to easier self-administration at home. However, it's not for acute episodes—oral meds are used first.[2][3]
| Treatment | Dosing Frequency | Administration | Key Advantage |
|-----------|------------------|----------------|--------------|
| UZEDY | 1-2 months | Subcutaneous | Home use possible |
| Invega Sustenna | 1 month | Intramuscular | Widely available |
| Abilify Maintena | 1 month | Intramuscular | Lower EPS risk |
What Are Common Side Effects and Risks?
Patients report weight gain (up to 7% body weight), drowsiness, and injection-site reactions. Serious risks include tardive dyskinesia, neuroleptic malignant syndrome, and high prolactin levels causing fertility issues. It's contraindicated in dementia-related psychosis due to increased death risk.[1]
When Does UZEDY's Patent Expire?
Core patents on UZEDY's formulation (using MedinCell's SteadyFlow tech) extend to 2037, with exclusivity until 2028. No Paragraph IV challenges filed yet per DrugPatentWatch.[4]
Can You Switch to UZEDY from Other Antipsychotics?
Yes, after stabilizing on oral risperidone (2-4 mg/day), switch directly without oral overlap. Monitor for 4-8 weeks post-injection as levels peak later than IM options.[2]
Sources:
[1] UZEDY Prescribing Information
[2] Clinical Trial Data (J Clin Psychiatry, 2023)
[3] FDA Approval Summary
[4] DrugPatentWatch.com - UZEDY Patents